Breast Biopsy Devices Market is set for steady growth to US$ 3.77 billion by 2033, led by North America 44% of global market share| Emerging Players- AOA DX, Kheiron Medical, and Hera-MI.

The Global Breast Biopsy Devices Market reached US$ 2.25 billion in 2024 and is expected to reach US$ 3.77 billion by 2033, growing at a CAGR of 6.1% during the forecast period 2025-2033.

Market growth is driven by the rising prevalence of breast cancer, increasing emphasis on early and accurate diagnosis, and growing adoption of minimally invasive biopsy procedures. Additionally, advancements in image-guided biopsy technologies, expanding use of vacuum-assisted and needle-based biopsy devices, and improving healthcare infrastructure and reimbursement coverage are further supporting market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/breast-biopsy-devices-market?pratik

United States: Key Industry Developments
✅ December 2025: AstraZeneca expanded its PCOS treatment portfolio with a new GLP-1 receptor agonist formulation, enhancing insulin sensitivity and weight management outcomes for patients with metabolic complications in PCOS. The approval highlighted improved ovulation rates by 25% in clinical trials.

✅ October 2025: The U.S. PCOS treatment market reached US$4.6 billion, driven by heightened awareness of long-term health risks and advances in hormonal therapies targeting insulin resistance. Key growth came from combination therapies integrating metabolic agents.

✅ September 2025: Pfizer launched an upgraded oral contraceptive for PCOS symptom management, featuring lower androgenic effects and better tolerability for adolescent patients, amid rising prevalence and regulatory support.

Asia Pacific / Japan: Key Industry Developments
✅ November 2025: Takeda Pharmaceutical introduced a novel anti-androgen therapy for PCOS in Japan, focusing on hirsutism and acne reduction with minimal side effects, supported by local health ministry subsidies for endocrine disorders. This addressed growing demand from lifestyle-related cases.

✅ October 2025: Otsuka collaborated on a digital health platform integrating PCOS monitoring with hormonal treatments, approved for Japanese markets to enable remote fertility tracking and personalized dosing amid rising diagnoses. [ from prior context adaptation]

✅ August 2025: Japanese regulators fast-tracked approval for biosimilar metformin variants tailored for PCOS, promoting cost-effective metabolic control and aligning with national initiatives for women's reproductive health investments.

Recent M&A Activity:-
Hologic Acquisition
✅ Hologic (US) - completed its acquisition of Gynesonics, Inc. (US) on January 6, 2025, for $350 million, enhancing its GYN Surgical portfolio with the Sonata System for minimally invasive intrauterine ultrasound-guided treatments, aligning with broader women's health diagnostics including breast biopsy advancements.
​
Mammotome Partnership
✅ Mammotome - entered an exclusive distribution agreement with Sirius Medical on February 27, 2025, for the US and Germany, integrating Sirius Pintuition® Surgical Marker Navigation System to improve breast cancer surgery precision post-biopsy, complementing Mammotome's biopsy site markers and gamma detection tools.

Market Segmentation Analysis:
By Product
Breast biopsy needles lead with 43.25% market share in 2024, favored for their precision in tissue extraction across various procedures. Guidance and imaging systems hold significant portions, growing at a projected 10.25% CAGR through 2030 due to demand for minimally invasive diagnostics. Other products like biopsy tables, localization wires, and assay kits contribute smaller shares, supporting procedural efficiency.
​
By Technique Type
Image-guided sampling dominates with 68.82% of the market in 2024, driven by accuracy in targeting lesions via ultrasound or MRI. Vacuum-assisted biopsy captures 35.53% revenue share, valued for larger tissue samples and reduced procedure times. Fine-needle aspiration biopsy grows fastest at 9.35% CAGR, appealing in resource-limited settings for its simplicity and low cost.
​
By Guidance Technology
Image-guided biopsy systems prevail, with mammography-guided stereotactic and ultrasound-guided options leading adoption for real-time visualization. MRI-guided biopsies gain traction for complex cases, while liquid biopsy techniques like NGS-based advance at 10.62% CAGR through 2030. Other guidance methods support specialized applications but hold minor shares.
​
By End-User
Hospitals and clinics command 52.82% revenue share in 2024 as primary sites for advanced imaging and multidisciplinary care. Hospitals and surgical centers further dominate due to extensive facilities. Independent diagnostic centers and breast care centers follow, expanding at 9.62% CAGR with telehealth integration.

📌 Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=breast-biopsy-devices-market?pratik

Growth Drivers:-
Market growth is driven by the rising prevalence of breast cancer and increasing awareness of early diagnosis.
The growing adoption of minimally invasive biopsy procedures with higher accuracy and reduced patient discomfort.
Advancements in imaging-guided biopsy technologies such as ultrasound-, MRI-, and stereotactic-guided systems.
The expanding use of breast cancer screening programs and government-led awareness initiatives.
Increasing healthcare expenditure and improved access to advanced diagnostic infrastructure.

Regional Insights:
North America commands the largest share of the Breast Biopsy Devices Market, estimated at around 44% in recent assessments, driven by advanced healthcare infrastructure, high breast cancer prevalence, substantial R&D investments, and favorable reimbursement policies in the US and Canada.
​
Europe follows as the second-largest region, benefiting from established medical device regulations, rising adoption in countries like Germany, France, and the UK, and growing awareness of early breast cancer diagnostics, though exact shares vary by report amid steady market expansion.
​
Asia Pacific ranks third in market share, yet exhibits the fastest growth potential with high CAGRs in nations such as China, India, and Japan, fueled by increasing healthcare investments, government screening initiatives, and expanding geriatric populations.

Speak to Our Analyst and Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/breast-cancer-liquid-biopsy-market?pratik

Key Players:

The major global players in the global breast biopsy market include STERYLAB S.r.l., Argon Medical Devices, Danaher Corporation, Cigna, Siemens Healthcare Private Limited, BD, Hologic, Inc., Devicor Medical Products, Inc., F. Hoffmann-La Roche Ltd, Cook among others.

Emerging Players:-
AOA DX, Kheiron Medical, and Hera-MI among others.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?pratik

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele

This release was published on openPR.